The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tuesday broker round-up UPDATE

Tue, 29th Jul 2014 09:37

Abderdeen Asset Management: Berenberg cuts target price from 530p to 510p and maintains a buy recommendation.African Barrick Gold: Numis takes target price from 260p to 330p upgrading from hold to buy.Anglo American: Deutsche Bank increases target price from 1590p to 1650p and reiterates a hold recommendation. Investec raises target price from 1630p to 1760p and keeps a hold recommendation.APR Energy: Investec places its target price (prev.: 880p) under review, while keeping a hold recommendation.Barclays: Numis upgrades from add to buy with a target price of 280p.Brammer: Investec cuts target price from 450p to 435p, while upgrading from hold to buy.BSkyB: Westhouse Securities upgrades from neutral to add with a target price of 985p.BTG: Jefferies ups target price from 525p to 760p upgrading from hold to buy.Compass Group: Deutsche Bank raises target price from 1025p to 1105p and retains a buy recommendation.Daily Mail & General Trust: Credit Suisse reinstates with a target price of 1040p and an outperform rating.Drax Group: Goldman Sachs cuts target price from 1098p to 1052p retaining a strong buy recommendation.Gem Diamonds: FinnCap ups target price from 211p to 261p and maintains a buy recommendation. Westhouse Securities ups target price from 220p to 235p and reiterates its buy recommendation.GKN: Numis upgrades from add to buy with a target price of 435p.GlaxoSmithKline: Berenberg reduces target price from 1740p to 1520p, while leaving its hold recommendation unchanged.Hiscox: Deutsche Bank cuts target price from 658p to 646p staying with its sell recommendation. Canaccord Genuity shifts target price from 705p to 710p and reiterates a hold recommendation.HSBC Holdings: Deutsche Bank reduces target price from 640p to 593p and reiterates a hold recommendation.Hutchison China Meditech: Panmure Gordon raises target price from 950p to 1200p keeping a buy recommendation.Informa: Canaccord Genuity cuts target price from 535p to 515p staying with its hold recommendation.Jardine Lloyd Thompson: Numis cuts target price from 1190p to 1120p downgrading from add to hold.Ladbrokers: Deutsche Bank lowers target price from 177p to 165p and keeps a buy recommendation.Lancashire Holdings: Berenberg reduces target price from 720p to 666p keeping a hold recommendation.Pace: Numis reduces target price from 420p to 360p and reiterates a hold recommendation.Petra Diamonds: Beaufort upgrades to buy. Numis ups target price from 220p to 240p, while downgrading from buy to add.Provident Financial: Espirito Santo raises target price from 1808p to 2012p and retains a neutral rating.Reckitt Benckiser: Credit Suisse raises target price from 5200p to 5500p and maintains an outperform rating. Numis downgrades from add to hold with a target price of 5600p.Sinclair IS Pharma: Jefferies lowers target price from 50p to 45p staying with its buy recommendation.Spectris: Goldman Sachs reduces target price from 3050p to 2770p and keeps its strong buy recommendation. Credit Suisse reduces target price from 2560p to 2370p and leaves its outperform rating unaltered. Canaccord Genuity reduces target price from 2700p to 2400p and downgrades from buy to hold.Sweett Group: N+1 Singer cuts target price from 61p to 45p retaining a buy recommendation.Tesco: Shore Capital upgrades from sell to hold.Treatt: Investec moves target price from 150p to 160p reiterating a hold recommendation.Tullett Prebon: Numis places both its target price (prev.: 299p) and its reduce rating under review. Liberum Capital places its target price (prev.: 240p) under review with a sell recommendation. Canaccord Genuity places both its target price and recommendation under review.William Hill: Deutsche Bank cuts target price from 435p to 415p leaving its buy recommendation unchanged.Zoopla Property: Credit Suisse initiates with a target price of 290p and an outperform rating.7Digital: Investec initiates with a target price of 37p and a buy recommendation.
More News
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 17:10

Miners, personal goods stocks drag FTSE 100 to two-week low

Burberry slips on rating downgrade

*

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 12:10

LONDON MARKET MIDDAY: Stocks down before Fed minutes and US PMI data

(Alliance News) - Stock prices in London were down at midday on Wednesday, in cautious trade ahead of key US data and central bank minutes in the afternoon.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
29 Dec 2023 13:01

LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023

(Alliance News) - Stock prices in London closed mixed on Friday, the final trading day of 2023, as the annual returns from UK equities were outshone by international markets.

Read more
20 Dec 2023 13:29

GSK buys rights to Hansoh Pharma antibody-drug conjugate

(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.

Read more
19 Dec 2023 15:36

German court quashes CureVac patent after challenge by BioNTech

CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue

*

Read more
18 Dec 2023 17:21

Energy stocks lift UK's FTSE 100, Vodafone shines

Vodafone jumps as Iliad offers to merge Italian units

*

Read more
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.